Last reviewed · How we verify

IBI343,Gemcitabine, Albumin-bound Paclitaxel — Competitive Intelligence Brief

IBI343,Gemcitabine, Albumin-bound Paclitaxel (IBI343,Gemcitabine, Albumin-bound Paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog. Area: Oncology.

phase 2 Nucleoside analog DNA polymerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IBI343,Gemcitabine, Albumin-bound Paclitaxel (IBI343,Gemcitabine, Albumin-bound Paclitaxel) — Innovent Biologics (Suzhou) Co. Ltd.. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IBI343,Gemcitabine, Albumin-bound Paclitaxel TARGET IBI343,Gemcitabine, Albumin-bound Paclitaxel Innovent Biologics (Suzhou) Co. Ltd. phase 2 Nucleoside analog DNA polymerase
Hepsera ADEFOVIR DIPIVOXIL Gilead Sciences marketed Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor DNA polymerase subunit gamma-1 2002-01-01
Gemzar gemcitabine Accord Hlthcare marketed Nucleoside Metabolic Inhibitor DNA polymerase (alpha/delta/epsilon) 1996-01-01
VALACYCLOVIR VALACYCLOVIR marketed Nucleoside analogue Viral DNA polymerase 1995-01-01
Cytarabine Cytarabine Nippon Shinyaku Co., Ltd. marketed Antimetabolite DNA polymerase 1969-01-01
AraC AraC University of California, San Diego marketed Nucleoside analog antimetabolite DNA polymerase; deoxycytidine kinase
Adefovir Dipivoxil Tablets Adefovir Dipivoxil Tablets Sun Yat-sen University marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase and DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog class)

  1. Third Affiliated Hospital, Sun Yat-Sen University · 2 drugs in this class
  2. Actuate Therapeutics Inc. · 2 drugs in this class
  3. City of Hope Medical Center · 1 drug in this class
  4. Cooperative Study Group A for Hematology · 1 drug in this class
  5. Genzyme, a Sanofi Company · 1 drug in this class
  6. Hospices Civils de Lyon · 1 drug in this class
  7. Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class
  8. Osaka Medical Center for Cancer and Cardiovascular Diseases · 1 drug in this class
  9. Tanabe Pharma Corporation · 1 drug in this class
  10. The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IBI343,Gemcitabine, Albumin-bound Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/ibi343-gemcitabine-albumin-bound-paclitaxel. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: